Objective: To discuss current and potential treatment options for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA). Data Sources: A MEDLINE search (1966-January 2007 ...

The agent MRX-I, an oral oxazolidinone antibiotic, targets infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and ...

The following is a summary of “Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA ...

Dalba vancin and oritavancin have shown bactericidal activity against MRSA, VRSA, VRE, and DRSP and are undergoing the final stages of clinical trials (Bradley, 2005; Hoffman-Roberts et al., ...

Patients colonized with AMR pathogens showed high risk for infection with the same pathogen for up to 2 years, indicating a time window for decolonization interventions.

Department of Chemistry, University of California, Irvine, Irvine, California 92697, United States Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, California 92697, ...

Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin ...

2019). The results of the current studies indicate an incomplete removal of resistant enterococci, including VRE strains belonging to clinically significant sequence types, during wastewater treatment ...